| Literature DB >> 24052853 |
Mala Nath1, Hitendra Singh, George Eng, Xueqing Song.
Abstract
Reaction(s) of 5'-guanosine monophosphate (5'GMP) with di- and triorganotin(IV) chloride(s) led to formation of organotin(IV) derivatives of general formulae, [R2Sn(5'-GMP)·H2O] n and [(R'3Sn)2(5'-GMP)·H2O] n , where R = Me, n-Bu, and Ph; R' = Me, i-Pr, n-Bu, and Ph; (5'-GMP)(2-) = 5'-guanosine monophosphate. An attempt has been made to prove the structures of the resulting derivatives on the basis of FT-IR, multinuclear (1)H, (13)C, and (119)Sn NMR and (119)Sn Mössbauer spectroscopic studies. These investigations suggest that both di- and triorganotin(IV)-5'-guanosine monophosphates are polymeric in which (5'-GMP)(2-) is bonded through phosphate group resulting in a distorted trigonal bipyramidal geometry around tin. The ribose conformation in all of the derivatives is C3'-endo, except diphenyltin(IV) and tri-i-propyltin(IV) derivatives where it is C2'-endo. All of the studied derivatives exhibited mild-to-moderate anti-inflammatory activity (~15.64-20.63% inhibition) at 40 mg kg(-1) dose and LD50 values > 400 mg kg(-1) in albino rats.Entities:
Year: 2012 PMID: 24052853 PMCID: PMC3767334 DOI: 10.5402/2012/873035
Source DB: PubMed Journal: ISRN Org Chem ISSN: 2090-5149
Scheme 1Reaction path ways for di- and triorganotin(IV) derivatives of (5′-GMP)2−.
119Sn Mössbauer data (80 K) of di- and triorganotin(IV) derivatives of (5′-GMP)2−.
| Complex | (Q.S.)a | (I.S.)a |
|
|
|
|---|---|---|---|---|---|
| (mm s−1) | (mm s−1) | (Q.S./I.S.) | |||
| [Me2Sn(5′-GMP)·H2O] | 3.55 | 1.14 | 3.11 | 2.00 | 2.00 |
| [ | 3.24 | 1.15 | 2.82 | 2.42 | 2.27 |
| [Ph2Sn(5′-GMP)·H2O] | 1.83 | 0.61 | 3.00 | 2.70 | 3.18 |
| [( | 3.35 | 1.40 | 2.39 | 1.88 | 2.00 |
| [( | 3.30 | 1.40 | 2.36 | 1.16 | 1.27 |
| [(Ph3Sn)2(5′-GMP)·H2O] | 2.52 | 0.95 | 2.65 | 3.00 | 3.63 |
aQS: quadrupole splitting; IS: isomeric shift relative to BaSnO3 and tin foil (splitting: 2.52 mm s−1); τ 1(L): half line-width left doublet component; τ 2(R): half line-width right doublet component (mm s−1).
Figure 1Possible isomers of R3SnL (where L = a bidentate ligand).
Figure 2Proposed structures of triorganotin(IV) derivatives of (5′-GMP)2−.
Figure 3Proposed structures of diorganotin(IV) derivatives of (5′-GMP)2−.
1H, 13C, and 19Sn NMR spectral data of di- and triorganotin(IV) derivatives of (5′-GMP)2− at 300 MHz in DMSO-d6.
| Ligand/Complex no.a |
|
|---|---|
| Na2(5′-GMP) (500 MHz) | N(1)-H: 10.67 (s, 1H); NH2: 6.48 (s, 2H); H-8: 7.95 (s, 1H); H-1′: 5.70 (d, 5.0 Hz, 1H); H-2′: 4.40 (s, 1H); 2′-OH: 5.42 (d, 5.5 Hz) and 5.14 (d, 3.0 Hz, 1H); H-3′: 4.09 (d, 4.0 Hz, 1H); 3′-OH: 5.06 (t, 4.5 Hz, 1H); H-4′: 3.87 (d, 3.0 Hz, 1H); H-5′: 3.55−3.51 (m)d and 3.64−3.60 (m, 2H); C-2: 153.6; C-4: 151.3; C-5: 116.6; C-6: 156.7; C-8: 135.6; C-1′: 86.3; C-2′: 73.6; C-3′: 70.3; C-4′: 85.2; C-5′: 61.3 |
|
| |
| [Me2Sn(5′-GMP)·H2O] | N(1)-H: 10.74 (s, 1H); NH2: 6.52 (s, 2H); H-8: 7.95 (s, 1H); H-1′: 5.71 (s, 1H); H-2′: 4.44 (s, 1H); 2′-OH: 5.41 (s, 1H); H-3′: 4.14 (s, 1H); 3′-OH: 5.26 (s, 1H); H-4′: 4.00 (br s, 1H); H-5′: 3.46 (d, 3.0 Hz, 2H); H- |
|
| |
| [ | N(1)-H: 10.74 (s, 1H); NH2: 6.63 (t, 3.5 Hz, 2H); H-8: 7.91 (s, 1H); H-1′: 5.76 (s, 1H); H-2′: 4.16 (s, 1H); 2′-OH: 5.53 (s, 1H); H-3′: 4.03 (s, 1H); 3′-OH: 4.48 (s, 1H); H-4′: 3.93 (br s, 1H); H-5′: 3.52 (s), 3.43 (d, 3.0 Hz, 2H); H- |
|
| |
| [Ph2Sn(5′-GMP)·H2O] | N(1)-H: 10.76 (s, 1H); NH2: 6.58 (s, 2H); H-8: 7.92 (s, 1H); H-1′: 5.79 (s, 1H); H-2′: 4.46 (s, 1H); 2′-OH: 5.57 (s, 1H); H-3′: 4.10 (s, 1H); 3′-OH: 5.38 (s, 1H); H-4′: 3.91 (s, 1H)c; H-5′: 3.66 (br d, 2H); H- |
|
| |
| [(Me3Sn)2(5′-GMP)·H2O] | N(1)-H: 10.67 (s, 1H); NH2: 6.49 (s, 2H); H-8: 7.93 (s, 1H); H-1′: 5.70 (s, 1H); H-2′: 4.44 (s, 1H); 2′-OH: 5.37 (s, 1H); H-3′: 4.15 (s, 1H); 3′-OH: 5.22 (s, 1H); H-4′: 3.98 (d, 7.5 Hz, 1H); H-5′: 3.36 (br d, 2H); H- |
|
| |
| [( | N(1)-H: 10.76 (s, 1H); NH2: 6.60 (s, 2H); H-8: 7.73 (s, 1H); H-1′: 5.68 (d, 6.0 Hz, 1H); H-2′: 4.36, (4.48) (s, 1H); 2′-OH: 5.55 (s, 1H); H-3′: 4.07 (s, 1H); 3′-OH: 5.41 (s, 1H); H-4′: 3.94 (br s, 1H); H-5′: 3.73 (br s, 2H); H- |
|
| |
| [( | N(1)-H: 10.67 (s, 1H); NH2: 6.51 (s, 2H); H-8: 7.62 (s, 1H); H-1′: 5.69 (s, 1H); H-2′: 4.26 (s, 1H); 2′-OH: 5.50 (s, 1H); H-3′: 3.96 (d, 18 Hz, 1H); 3′-OH: 5.11 (br s, 1H); H-4′: 3.71 (br s, 1H); H-5′: 3.40 (s, 2H); H- |
|
| |
| [(Ph3Sn)2(5′-GMP)·H2O] | N(1)-H: 10.66 (s, 1H); NH2: 6.51 (s, 2H); H-8: 7.75 (s, 1H); H-1′: 5.69 (s, 1H); H-2′: 4.41 (s, 1H); 2′-OH: 5.42 (s, 1H); H-3′: 4.10 (s, 1H); 3′-OH: 5.19 (s, 1H); H-4′: 3.96 (s, 1H); H-5′: 3.41, (3.17), (s, 2H); H- |
aAccording to Experimental section; bhomonuclear proton-proton coupling multiplet abbreviations given in parentheses: s: singlet; d: doublet; t: triplet; br: broad; m: multiplet; cfused singlet; doverlapping multiplets; weak signals in parantheses; resonances H-β (a) and H-β (b) may be interchanged(see Scheme 2).
Anti-inflammatory activity and toxicity data of di- and triorganotin(IV) derivatives of (5′-GMP)2−.
| Complex/standard drug | Anti-inflammatory activitya | Toxicity LD50 | |
|---|---|---|---|
| Dose (mg/kg p.o.) | % inhibition | mg/kg p.o. | |
| [Me2Sn(5′-GMP)·H2O] | 40 | 18.12 | >400 |
| [ | 40 | 16.32 | >400 |
| [Ph2Sn(5′-GMP)·H2O] | 40 | 19.22 | >400 |
| [( | 40 | 15.64 | >400 |
| [( | 40 | 17.34 | >400 |
| [(Ph3Sn)2(5′-GMP)·H2O] | 40 | 20.63 | >400 |
| Phenyl butazone | 40 | 34.56 | >2000 |
a% inhibition in paw edema = [(DC − DT)/DC] × 100, where DT and DC are the mean volumes of paw edema in drug-treated and control groups. Standard deviation (σ) in DC is <0.09 and in DT <0.15.
Standard error in mean [(SEM) = (σ/(N)1/2)] in DC is <0.040 and in DT <0.067.